Hematologic recovery in mice transplanted with bone marrow stem cells expressing anti-human immunodeficiency virus genes.
We have used a mouse bone marrow transplantation (BMT) model to study the safety of retrovirus-mediated transfer of anti-HIV genes (RevM10 and HIV-1 pol antisense) into hematopoietic stem/progenitor cells (HSPCs). In particular, we have monitored the hematologic recovery post-BMT and transgene expression in myeloid and lymphoid lineages, and analyzed tissue sections for evidence of any transgene-related pathological condition. Expression of anti-HIV genes had no effect on kinetics of hematologic recovery post-BMT. The average time to reach 20% of normal cell counts was 15-17 days for white blood cells and 12-14 days for platelets, and the average time to reach complete recovery was 42-56 days for leukocytes and 104-161 days for platelets. Hematocrit levels were not significantly affected by irradiation and transplantation procedures. Donor chimerism was uniformly > or =90% in all transplanted animals. At 4-5 weeks post-BMT transgene expression was detected in peripheral blood leukocytes in 100% of the animals and ranged from 4.5 to 44.7%. In a majority of the animals the percentage of transgene-expressing cells in circulation decreased over time but remained detectable for the length of the study (>6 months). Expression was detected in all analyzed cell lineages (RBCs, platelets, monocytes, granulocytes, and T and B cells). Relative counts of various leukocytes (Mac1+ monocytes, Gr1+ granulocytes, CD3+ T cells, and B220+ B cells) were normal. There were no treatment-related histopathological changes in a wide range of tissues examined. In addition, there were no treatment effects on differential leukocyte counts, and morphology of peripheral blood and bone marrow brush smears. In summary, transfer and expression of the RevM10 and the HIV-1 antisense genes into hematopoietic stem/progenitor cells in vivo appears safe. We propose that the mouse bone marrow transplantation model could be used to evaluate some safety aspects of HSPC-based gene therapies.
Morel
F
F
SyStemix, Inc., Palo Alto, CA 94304, USA.
Salimi
S
S
Markovits
J
J
Austin
T W
TW
Plavec
I
I
D000818:Animals; D016026:Bone Marrow Transplantation; D019070:Cell Lineage; D016373:DNA, Antisense / Q000235:genetics*; D004279:DNA, Viral / Q000235:genetics; D005260:Female; D015684:Gene Products, pol / Q000096:biosynthesis / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics / Q000502:physiology; D006678:HIV / Q000235:genetics* / Q000502:physiology; D006412:Hematopoietic Stem Cells / Q000473:pathology / Q000502:physiology*; D008297:Male; D051379:Mice; D008954:Models, Biological; D012190:Retroviridae / Q000235:genetics; D014018:Tissue Distribution; D014162:Transfection; D054302:pol Gene Products, Human Immunodeficiency Virus
D016373:DNA, Antisense; D004279:DNA, Viral; D015684:Gene Products, pol; C060467:HIV pol protein p65; D054302:pol Gene Products, Human Immunodeficiency Virus